Amyloidosis in Human Inborn Errors of Immunity Predicts Poor Prognosis
AA amyloidosis in IEI is associated with severe morbidity and mortality. Early diagnosis and management of IEI are crucial to prevent amyloidosis development. However, colchicine appears ineffective once amyloidosis has occurred, highlighting the need for further research into early diagnostic biomarkers and novel treatment options.
Authors
- Anar Tağıyev (ORCID: https://orcid.org/0000-0003-1054-7643)
- Elif Soyak Aytekin (ORCID: https://orcid.org/0000-0002-2329-7543)
- Arzu Sağlam (ORCID: https://orcid.org/0000-0002-0076-8293)
- Saliha Esenboğa (ORCID: https://orcid.org/0000-0003-0562-9863)
- Deniz Çağdaş (ORCID: https://orcid.org/0000-0003-2213-4627)
- Onat Silleli
- Fevzi Demirel (ORCID: https://orcid.org/0000-0003-0925-7366)
- İncinur Samur
Institutions
- Gülhane Askerî Tıp Akademisi (TR)
- Hacettepe University Hospital (TR)
- Baku Engineering University (AZ)
- Hacettepe University (TR)
Publication Details
- Journal
- Journal of Clinical Immunology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1007/s10875-025-01875-1
- Citations
- 1
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.80
Funders
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
- Hacettepe Üniversitesi